Wyeth Research is conducting the Intoract study with the support and assistance of Roche and Genentech. The primary end point of the Intoract study is independently assessed progression-free survival (PFS) of patients in all risk groups. Secondary end points include safety, investigator-assessed PFS, independently assessed objective response rate and overall survival.
Joseph Camardo, senior vice president of global medical affairs at Wyeth Pharmaceuticals, said: “In the Intoract study, we hope to learn more about whether combining Torisel with other agents in the first-line setting may further improve outcomes for patients with this devastating disease.”